David Sans is responsible for leading Calidi’s corporate development efforts. He is fully FINRA registered as a Managing Director in Healthcare Banking and has led IPOs onto NASDAQ and NYSE. David previously served several positions at Novartis, Pfizer, and ImClone Systems leading to a $5Bn acquisition by Eli Lilly and reporting to Carl Icahn’s Team during the M&A transaction. David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis during the launch of Glivec® (imatinib) in Switzerland. David served as an Executive at Mount Sinai Health Systems completing multiple transactions with Philips, LabCorp, and Agilent. David served as a Board Member of the Lymphatic Education & Research Network. In New York and he holds a Ph.D. in Chemical Engineering from University Ramon Llull in collaboration with the ETH in Zürich and came to the US under the Scientist of National Interest Program, received an MBA in Business Law from Fordham in NYC, and is the recipient of the Don Sheehan International Scholarship from the Wharton School of Business. David holds a Fellowship in Anti-Aging and Regenerative Medicine FAARM and passed FINRA Series 7, 63, 17, and 55 exams.
David Sans Ph.D., MBA
Chief Corporate Development